Citigroup Inc. Sells 16,797 Shares of Prestige Consumer Healthcare Inc. $PBH

Citigroup Inc. cut its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 23.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,553 shares of the company’s stock after selling 16,797 shares during the quarter. Citigroup Inc. owned approximately 0.11% of Prestige Consumer Healthcare worth $3,467,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wealth Alliance LLC lifted its holdings in Prestige Consumer Healthcare by 22.4% in the 3rd quarter. Wealth Alliance LLC now owns 4,088 shares of the company’s stock worth $255,000 after buying an additional 747 shares during the period. King Luther Capital Management Corp purchased a new stake in Prestige Consumer Healthcare in the third quarter worth $2,268,000. First National Bank of Omaha bought a new stake in Prestige Consumer Healthcare in the third quarter valued at $370,000. Heartland Advisors Inc. boosted its holdings in Prestige Consumer Healthcare by 41.4% in the third quarter. Heartland Advisors Inc. now owns 64,376 shares of the company’s stock valued at $4,017,000 after acquiring an additional 18,851 shares in the last quarter. Finally, Texas Yale Capital Corp. increased its position in Prestige Consumer Healthcare by 15.8% during the 3rd quarter. Texas Yale Capital Corp. now owns 8,430 shares of the company’s stock valued at $526,000 after purchasing an additional 1,150 shares during the period. Institutional investors own 99.95% of the company’s stock.

Insider Transactions at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the sale, the vice president directly owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.40% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $68.14 on Friday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.25 and a fifty-two week high of $90.04. The firm’s 50-day simple moving average is $65.77 and its two-hundred day simple moving average is $63.58. The stock has a market cap of $3.22 billion, a PE ratio of 18.03, a price-to-earnings-growth ratio of 2.17 and a beta of 0.41. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. During the same period in the prior year, the firm earned $1.22 earnings per share. The business’s revenue for the quarter was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PBH has been the subject of several research analyst reports. Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Jefferies Financial Group lowered their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Hold” and an average target price of $80.60.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).